Analysis of ovulation induction effects of two kinds of recombinant human follicle-stimulating hormone injections among different patients
Objective:To investigate the efficacy and safety of two kinds of recombinant human follicle-stimulating hormone(rFSH)with different glycan modification profiles for clinical use among different patients undergoing controlled ovulation hyperstimulation(COH).Methods:Clinical data from a total of 320 cycles of COH using Follitrope® or Puregon® between January 2022 and December 2022 at Reproductive Medicine Center of Zhongshan Hospital,Fudan University were retrospectively analyzed.According to the type of rFSH used in COH,patients were divided into group A(Follitrope®,95 cycles)and group B(Puregon®,225 cycles).The differences between the two groups were compared in terms of starting doses of rFSH,duration of treatment,levels of hormones and endometrial thickness on HCG day,number of oocytes retrieved,metaphase[[oocyte rate,the fertilization rate,the cleavage rate,effective embryo rate,oocyte utilization rate and embryo utilization rate.Results:The number of oocytes retrieved in group A was comparable to that of group B[(11.2±7.0)vs.(12.9±7.3),P=0.059],provided that there were some differences between the two groups in terms of age[(34.9±4.9)years old vs.(33.3±4.5)years old,P=0.006],BMI[(22.5±3.2)kg/m2 vs.(21.6± 2.6)kg/m2,P=0.027)].In the antagonist COH cycles,the age was similar between the two groups(P＞0.05),and there was no statistical differences in the outcome indicators such as the number of oocytes retrieved[(13.7±7.1)vs.(14.8±7.6),P=0.340].All patients were further divided into older subgroups(≥35 years old)and younger subgroups(＜35 years old).In the older subgroup,the fertilization rate[(78.1±19.6)％vs.(69.1±25.8)％,P=0.039],the cleavage rate[(98.9±3.2)％vs.(93.7± 22.1)％,P=0.039],and oocyte utilization rate[(44.9±30.6)％vs.(34.1±23.5)％,P=0.037]of group A were significantly higher than those of group B.In the younger subgroup,there were no significant differences in various indicators(P＞0.05)between group A and group B.The COH protocol and age were identified as predictors of the number of oocytes acquired by stepwise multiple regression analysis(P＜0.001),explaining 28.8％of the response variability.Conclusions:Similar oocytes and embryo retrieval outcomes were found when compared Puregon® to Follitrope®,but the quality of oocytes induced by Follitrope® would be higher in older patients.
Recombinant human follicle-stimulating hormoneControlled ovarian hyperstimulationAdvanced ageGlycosylation
万方数据
维普
